Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Daily Top 10 COVID-19 papers

DEU | ENG | ESP | FRA | ITA | POR | TUR | VNM


  Bladder Cancer

  Free Subscription


30.03.2020

1 Acta Med Okayama
1 Adv Clin Exp Med
1 Biomed Pharmacother
1 BMC Urol
1 Cancer Causes Control
1 Cancer Lett
1 Cancer Treat Rev
1 Clin Genitourin Cancer
1 Clin Lung Cancer
2 Curr Opin Urol
1 Eur J Clin Nutr
1 Eur Radiol
1 Eur Rev Med Pharmacol Sci
3 Eur Urol
4 Eur Urol Oncol
1 Expert Rev Anticancer Ther
1 Front Genet
1 Front Pharmacol
1 Hum Cell
1 J Am Soc Cytopathol
6 J Cancer
1 J Pharm Biomed Anal
3 J Urol
1 Mater Sci Eng C Mater Biol Appl
2 Minerva Urol Nefrol
1 Oncol Lett
1 PeerJ
2 PLoS One
1 Tunis Med
1 Urol Int
5 Urol Oncol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Acta Med Okayama

  1. YANAGIHARA Y, Nishida K, Watanabe R, Koyama K, et al
    Feasibility of Laparoscopic Radical Cystectomy in Elderly Patients: A Comparative Analysis of Clinical Outcomes in a Single Institution.
    Acta Med Okayama. 2019;73:417-418.
    PubMed         Abstract available


    Adv Clin Exp Med

  2. ADAMCZYK P, Juszczak K, Kadlubowski M, Ostrowski A, et al
    Can laparoscopic cystectomy become the method of choice in the treatment of invasive urothelial urinary bladder cancer?
    Adv Clin Exp Med. 2020 Mar 24. doi: 10.17219/acem/115084.
    PubMed         Abstract available


    Biomed Pharmacother

  3. GONG P, Xu R, Zhuang Q, He X, et al
    A novel circular RNA (hsa_circRNA_102336), a plausible biomarker, promotes the tumorigenesis by sponging miR-515-5p in human bladder cancer.
    Biomed Pharmacother. 2020;126:110059.
    PubMed         Abstract available


    BMC Urol

  4. ZHANG J, Zhou X, Ding H, Wang L, et al
    The prognostic value of routine preoperative blood parameters in muscle-invasive bladder cancer.
    BMC Urol. 2020;20:31.
    PubMed         Abstract available


    Cancer Causes Control

  5. LI Y, Hendryx MS, Xun P, He K, et al
    The association between type 2 diabetes mellitus and bladder cancer risk among postmenopausal women.
    Cancer Causes Control. 2020 Mar 19. pii: 10.1007/s10552-020-01294.
    PubMed         Abstract available


    Cancer Lett

  6. TAKEYAMA Y, Kato M, Tamada S, Azuma Y, et al
    Myeloid-derived suppressor cells are essential partners for immune checkpoint inhibitors in the treatment of cisplatin-resistant bladder cancer.
    Cancer Lett. 2020 Mar 18. pii: S0304-3835(20)30132.
    PubMed         Abstract available


    Cancer Treat Rev

  7. MORALES-BARRERA R, Suarez C, Gonzalez M, Valverde C, et al
    The future of bladder cancer therapy: Optimizing the inhibition of the fibroblast growth factor receptor.
    Cancer Treat Rev. 2020;86:102000.
    PubMed         Abstract available


    Clin Genitourin Cancer

  8. RUPLIN AT, Spengler AMZ, Montgomery RB, Wright JL, et al
    Downstaging of Muscle-Invasive Bladder Cancer Using Neoadjuvant Gemcitabine and Cisplatin or Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Single Regimens or as Switch Therapy Modalities.
    Clin Genitourin Cancer. 2020 Feb 22. pii: S1558-7673(20)30044.
    PubMed         Abstract available


    Clin Lung Cancer

  9. TOLWIN Y, Gillis R, Agmon IN, Shrem NS, et al
    Increased Incidence of Lung Cancer Among Patients With Superficial Transitional Cell Carcinoma: A Potential Risk Cohort for Lung Cancer Screening.
    Clin Lung Cancer. 2019 Jun 18. pii: S1525-7304(19)30152.
    PubMed         Abstract available


    Curr Opin Urol

  10. FABA OR, Palou J
    Emerging approaches and future perspectives in nonmuscle invasive bladder cancer.
    Curr Opin Urol. 2020 Mar 19. doi: 10.1097/MOU.0000000000000766.
    PubMed        

  11. SUNG HH, Lerner SP
    Utility of lymphadenectomy in bladder cancer: where do we stand?
    Curr Opin Urol. 2020 Mar 19. doi: 10.1097/MOU.0000000000000750.
    PubMed         Abstract available


    Eur J Clin Nutr

  12. LUO J, Shivappa N, Hebert JR, Xu X, et al
    Dietary inflammatory index and bladder cancer risk: a prospective study.
    Eur J Clin Nutr. 2020 Mar 19. pii: 10.1038/s41430-020-0602.
    PubMed         Abstract available


    Eur Radiol

  13. LIN P, Wen DY, Chen L, Li X, et al
    A radiogenomics signature for predicting the clinical outcome of bladder urothelial carcinoma.
    Eur Radiol. 2020;30:547-557.
    PubMed         Abstract available


    Eur Rev Med Pharmacol Sci

  14. WANG Y, Ma DL, Yu CH, Sha KF, et al
    MicroRNA-370 suppresses SOX12 transcription and acts as a tumor suppressor in bladder cancer.
    Eur Rev Med Pharmacol Sci. 2020;24:2303-2312.
    PubMed         Abstract available


    Eur Urol

  15. BAI Y, Yang Y, Tang Y
    Re: Andrea Necchi, Marco Bandini, Giuseppina Calareso, et al. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-0
    Eur Urol. 2020 Mar 18. pii: S0302-2838(20)30149.
    PubMed        

  16. MOSTAFID H, Babjuk M, Bochner B, Lerner SP, et al
    Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer.
    Eur Urol. 2020 Mar 16. pii: S0302-2838(20)30146.
    PubMed         Abstract available

  17. NECCHI A, Gallina A, Dyrskjot L, Roupret M, et al
    Converging Roads to Early Bladder Cancer.
    Eur Urol. 2020 Mar 17. pii: S0302-2838(20)30141.
    PubMed        


    Eur Urol Oncol

  18. BJURLIN MA, Matulewicz RS, Roberts TR, Dearing BA, et al
    Carcinogen Biomarkers in the Urine of Electronic Cigarette Users and Implications for the Development of Bladder Cancer: A Systematic Review.
    Eur Urol Oncol. 2020 Mar 7. pii: S2588-9311(20)30029.
    PubMed         Abstract available

  19. DE JONG JJ, Boormans JL, van Rhijn BWG, Seiler R, et al
    Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.
    Eur Urol Oncol. 2020 Mar 20. pii: S2588-9311(20)30035.
    PubMed         Abstract available

  20. KAMAT AM, Lerner SP, O'Donnell M, Georgieva MV, et al
    Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2020 Mar 19. pii: S2588-9311(20)30031.
    PubMed         Abstract available

  21. WOO S, Panebianco V, Narumi Y, Del Giudice F, et al
    Diagnostic Performance of Vesical Imaging Reporting and Data System for the Prediction of Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Eur Urol Oncol. 2020 Mar 18. pii: S2588-9311(20)30032.
    PubMed         Abstract available


    Expert Rev Anticancer Ther

  22. GOTO T, Miyamoto H
    Why has the prognosis for muscle-invasive bladder cancer not significantly improved after decades of therapeutic advancements?
    Expert Rev Anticancer Ther. 2020 Mar 24:1-3. doi: 10.1080/14737140.2020.1744437.
    PubMed        


    Front Genet

  23. WANG X, Meng R, Hu QM
    LINC00319-Mediated miR-3127 Repression Enhances Bladder Cancer Progression Through Upregulation of RAP2A.
    Front Genet. 2020;11:180.
    PubMed         Abstract available


    Front Pharmacol

  24. WEI X, Wang B, Wang Q, Yang X, et al
    MiR-362-5p, Which Is Regulated by Long Non-Coding RNA MBNL1-AS1, Promotes the Cell Proliferation and Tumor Growth of Bladder Cancer by Targeting QKI.
    Front Pharmacol. 2020;11:164.
    PubMed         Abstract available


    Hum Cell

  25. CHEN W, Jiang T, Mao H, Gao R, et al
    SNHG16 regulates invasion and migration of bladder cancer through induction of epithelial-to-mesenchymal transition.
    Hum Cell. 2020 Mar 24. pii: 10.1007/s13577-020-00343.
    PubMed         Abstract available


    J Am Soc Cytopathol

  26. GELWAN E, Zhang ML, Allison DB, Cowan ML, et al
    Variability among observers utilizing the CellSolutions BestCyte Cell Sorter imaging system for the assessment of urinary tract cytology specimens.
    J Am Soc Cytopathol. 2019;8:18-26.
    PubMed         Abstract available


    J Cancer

  27. BORGNA V, Lobos-Gonzalez L, Guevara F, Landerer E, et al
    Targeting antisense mitochondrial noncoding RNAs induces bladder cancer cell death and inhibition of tumor growth through reduction of survival and invasion factors.
    J Cancer. 2020;11:1780-1791.
    PubMed         Abstract available

  28. XIE F, Zhao N, Zhang H, Xie D, et al
    Circular RNA CircHIPK3 Promotes Gemcitabine Sensitivity in Bladder Cancer.
    J Cancer. 2020;11:1907-1912.
    PubMed         Abstract available

  29. FU G, Xu Z, Chen X, Pan H, et al
    CDCA5 functions as a tumor promoter in bladder cancer by dysregulating mitochondria-mediated apoptosis, cell cycle regulation and PI3k/AKT/mTOR pathway activation.
    J Cancer. 2020;11:2408-2420.
    PubMed         Abstract available

  30. YAN X, Fu X, Guo ZX, Liu XP, et al
    Construction and validation of an eight-gene signature with great prognostic value in bladder cancer.
    J Cancer. 2020;11:1768-1779.
    PubMed         Abstract available

  31. XIONG T, Huang C, Li J, Yu S, et al
    LncRNA NRON promotes the proliferation, metastasis and EMT process in bladder cancer.
    J Cancer. 2020;11:1751-1760.
    PubMed         Abstract available

  32. WANG Z, Gao W, Li J, Wang T, et al
    Development and Validation of a Novel Recurrence Risk Stratification for Initial Non-Muscle Invasive Bladder Cancer in the Han Chinese Population.
    J Cancer. 2020;11:1668-1678.
    PubMed         Abstract available


    J Pharm Biomed Anal

  33. COOK T, Ma Y, Gamagedara S
    Evaluation of statistical techniques to normalize mass spectrometry-based urinary metabolomics data.
    J Pharm Biomed Anal. 2020;177:112854.
    PubMed         Abstract available


    J Urol

  34. VENKATRAMANI V, Reis IM, Castle EP, Gonzalgo ML, et al
    Predictors of Recurrence, and Progression-Free and Overall Survival following Open versus Robotic Radical Cystectomy: Analysis from the RAZOR Trial with a 3-Year Followup.
    J Urol. 2020;203:522-529.
    PubMed         Abstract available

  35. MULLER G, Butea-Bocu M, Brock O, Hanske J, et al
    Association between Development of Metabolic Acidosis and Improvement of Urinary Continence after Ileal Neobladder Creation.
    J Urol. 2020;203:585-590.
    PubMed         Abstract available

  36. ZHANG JH, Ericson KJ, Thomas LJ, Knorr J, et al
    Large Single Institution Comparison of Perioperative Outcomes and Complications of Open Radical Cystectomy, Intracorporeal Robot-Assisted Radical Cystectomy and Robotic Extracorporeal Approach.
    J Urol. 2020;203:512-521.
    PubMed         Abstract available


    Mater Sci Eng C Mater Biol Appl

  37. ALBAN L, Monteiro WF, Diz FM, Miranda GM, et al
    New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer.
    Mater Sci Eng C Mater Biol Appl. 2020;110:110662.
    PubMed         Abstract available


    Minerva Urol Nefrol

  38. BRASSETTI A, Tuderti G, Anceschi U, Ferriero M, et al
    Combined reporting of surgical quality, cancer control and functional outcomes of robot-assisted radical cystectomy with intracorporeal orthotopic neobladder into a novel trifecta.
    Minerva Urol Nefrol. 2019;71:590-596.
    PubMed         Abstract available

  39. ALBISINNI S, Veccia A, Aoun F, Diamand R, et al
    A systematic review and meta-analysis comparing the outcomes of open and robotic assisted radical cystectomy.
    Minerva Urol Nefrol. 2019;71:553-568.
    PubMed         Abstract available


    Oncol Lett

  40. YUAN S, Luan X, Chen H, Shi X, et al
    Long non-coding RNA EGFR-AS1 sponges micorRNA-381 to upregulate ROCK2 in bladder cancer.
    Oncol Lett. 2020;19:1899-1905.
    PubMed         Abstract available


    PeerJ

  41. WU H, Zhang X, Han D, Cao J, et al
    Tumour-associated macrophages mediate the invasion and metastasis of bladder cancer cells through CXCL8.
    PeerJ. 2020;8:e8721.
    PubMed         Abstract available


    PLoS One

  42. EVERS J, Grotenhuis AJ, Aben KKH, Kiemeney LALM, et al
    No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression.
    PLoS One. 2020;15:e0229384.
    PubMed         Abstract available

  43. REZAEE ME, Lynch KE, Li Z, MacKenzie TA, et al
    The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).
    PLoS One. 2020;15:e0230417.
    PubMed         Abstract available


    Tunis Med

  44. BOUHAJJA L, Farah F, Garbouj N, Rammeh S, et al
    Primary signet-ring cell carcinoma of the urinary bladder: A report of two cases.
    Tunis Med. 2019;97:167-169.
    PubMed         Abstract available


    Urol Int

  45. SUAREZ-IBARROLA R, Hein S, Farin E, Waldbillig F, et al
    Current Standards in the Endoscopic Management of Bladder Cancer: A Survey Evaluation among Urologists in German-Speaking Countries.
    Urol Int. 2020 Mar 25:1-7. doi: 10.1159/000506653.
    PubMed         Abstract available


    Urol Oncol

  46. JANISCH F, D'Andrea D, Iwata T, Kimura S, et al
    The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC).
    Urol Oncol. 2020 Mar 21. pii: S1078-1439(20)30043.
    PubMed         Abstract available

  47. BENDERSKA-SODER N, Hovanec J, Pesch B, Goebell PJ, et al
    Toward noninvasive follow-up of low-risk bladder cancer - Rationale and concept of the UroFollow trial.
    Urol Oncol. 2020 Mar 18. pii: S1078-1439(20)30007.
    PubMed         Abstract available

  48. MICHEL C, Robertson HL, Camargo J, Hamilton-Reeves JM, et al
    Nutrition risk and assessment process in patients with bladder cancer undergoing radical cystectomy.
    Urol Oncol. 2020 Mar 16. pii: S1078-1439(20)30060.
    PubMed         Abstract available

  49. OZCAN Y, Caglar F, Celik S, Demir AB, et al
    The role of cancer stem cells in immunotherapy for bladder cancer: An in vitro study.
    Urol Oncol. 2020 Mar 16. pii: S1078-1439(20)30062.
    PubMed         Abstract available

  50. FUJITA N, Hatakeyama S, Momota M, Tobisawa Y, et al
    Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Urol Oncol. 2020 Mar 20. pii: S1078-1439(20)30042.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: